By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ArmaGen Technologies, Inc. 

914 Colorado Avenue

Santa Monica  California  90401  U.S.A.
Phone: 310-917-1275 Fax: 310-917-1276



Company News
ArmaGen Technologies, Inc. Receives Rare Pediatric Disease Designation From FDA For AGT-181 For The Potential Treatment Of Hurler Syndrome (Mucopolysaccharidosis Type I) 11/5/2015 6:20:52 AM
ArmaGen Technologies, Inc. Announces First Patient Dosed In Phase 1/2a Clinical Trial Of AGT-181 For The Treatment Of Hurler Syndrome 9/2/2015 10:11:02 AM
ArmaGen Technologies, Inc. Achieves Clinical Milestone In Hunter Syndrome Collaboration With Shire (SHPGY) 6/15/2015 6:20:05 AM
ArmaGen Technologies, Inc. Announces FDA Acceptance Of IND Application For AGT-181 For The Treatment Of Hurler Syndrome 4/8/2015 6:15:13 AM
PacificGMP And ArmaGen Technologies, Inc. Announce Successful Manufacture Of Armagen's Investigational Enzyme Replacement Therapies, AGT-182 And AGT-181, For Phase 1 Clinical Trial 3/10/2015 6:40:25 AM
ArmaGen Technologies, Inc. To Present At Oppenheimer 25th Annual Healthcare Conference 12/5/2014 12:42:02 PM
ArmaGen Technologies, Inc. Licenses AGT-182 Rights To Shire For Up To $225M 7/23/2014 6:48:56 AM
ArmaGen Technologies, Inc. Receives Notice Of Allowance For U.S. Patent Covering Novel Investigational Therapy For Hunter Syndrome 6/17/2014 10:15:00 AM
ArmaGen Technologies, Inc. Expands Patent Portfolio With Issuance of Two Additional U.S. Patents 9/4/2013 10:34:28 AM
ArmaGen Technologies, Inc. Receives US Orphan Designation for Lead Product AGT-182 7/19/2013 9:05:03 AM